UK Community Advisory Board (UK-CAB)

UK-CAB 72: COVID-19 and CD4/immune system; CROI feedback and London patient


09.45 Webinar is open
10.00-10:45 Impact of COVID-19 on CD4/immune system – Dr Laura Waters, Mortimer Market Centre
10:45-10:55 BREAK
10:55-11.55 CROI feedback – Simon Collins
11.55-12.55 Special guest: London patient – Q&A
13.00 Meeting close

Slides and meeting report

Background reading

London Patient article

Financial support

The UK-CAB receives unrestricted funding from some pharmaceutical companies towards the direct costs of holding four meetings each year.

This funding supports the travel and accommodation costs for members to attend from outside London, plus the cost of catering. The content, programme and agenda for meetings is decided by the UK-CAB steering group in consultation with the wider membership. Funding is unconnected to meeting content.

Companies that develop and market medicines have a responsibility to actively engage with advocacy organisations. HIV positive people and their advocates should also be able to ask manufacturers directly about the safety and efficacy of their products. We should be involved in their proposals for future research.

For a list of companies that support the UK-CAB please see the “about us” page.